VXRT News and Press, Vaxart Inc. From 06/07/21

Pfizer and Moderna have already brought coronavirus vaccines to market. But that doesn't mean the window of opportunity is closed to others whose vaccine candidates are still in development. In this Motley Fool Live video recorded on May 28 , healthcare and cannabis bureau e...

SOUTH SAN FRANCISCO, Calif., June 07, 2021 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced that its executive officers, Andrei Floroiu, CEO,...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Vaxart  (NASDAQ: VXRT ) is an intriguing biotech company that is attempting to develop oral vaccines for a number of conditions, including most notably, Covid-19. If you ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips It’s tempting to view Vaxart (NASDAQ: VXRT ) as a company unfortunately one year too late. And it might be an accurate assessment. Though VXRT stock was tied to a compelling need, that is to address the novel c...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Investors looking for a high-risk, high-reward investment in a vaccine maker should consider buying a small amount of Vaxart (NASDAQ: VXRT ) stock. Source: Ascannio / Shutterstock.com Vaxart has developed a vacc...

The FDA has said yesterday it may turn down emergency use authorizations ((EUA)) for COVID-19 vaccines for the remainder of the pandemic unless the developers have not already begun discussion with the regulator, Reuters reported.Under a EUA, the FDA facilitates the availability and use ...

These Current & Former Penny Stocks Are Making Their Mark In 2021 Penny stocks have been a big focus for retail traders over the last few years. In fact, if you look at any of the top small-cap stock ETFs, the trend is clear right now. Since the depths of the pandemic drop, the Russ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Shares of clinical-stage biotech company Vaxart (NASDAQ: VXRT ) have cooled off considerably after gaining about 1,500% last year. However, it’s still plodding along in developing its oral Coronavirus vaccine c...

The coronavirus vaccine market is only a few months old, but it is already worth well over $1 billion. And while companies such as Moderna and Pfizer are currently leaders in this space, others are working to throw their hats into the ring. Two of them are Vaxart (NASDAQ: VXRT...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Vaxart (NASDAQ: VXRT ) tried to produce a Covid-19 vaccine that could be taken orally as a pill, but it failed. As a result, VXRT stock is probably headed down 85% to its cash per share level, or about $1.00. Sour...